OFFICE OF CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS
BPCA SUMMARY REVIEW

NDA 21-718

Brand Name:	Diflucan™ Oral Suspension
Generic Name:	Fluconazole
Dosage Form:	Oral Suspension
Dosage Strength:	10 mg/mL and 40 mg/mL
NDA Type:	Original NDA 505(b)(1)
Relevant IND/NDA	IND 63,849, NDA 19-949, NDA 19-950, NDA 20-322
Submission Date(s):	10/28/2003
Sponsor:	Pfizer Pharmaceutical Group
Reviewer:	Chandra S. Chaurasia, Ph.D.
Team Leader:	E. Dennis Bashaw, Pharm. D.
OCPB Division:	DPE III (HFD-880)
OND Division:	ODE V (HFD-540)

1. EXECUTIVE SUMMARY

1.1. Background

- In the current NDA 21-718, the Sponsor has submitted Pediatric Study Reports in support of its request for Pediatric Exclusivity Determination for Diflucan™ for Oral Suspension 10 mg/mL and 40 mg/mL. The firm has responded to original Written Request issued by the Division of Dermatology and Dental Drug Products on December 31, 2001 and the subsequent amendment dated June 7, 2002. The report consists of data from studies conducted to meet the elements of the Written Request under IND 63, 849.

- In the current submission, the firm has conducted three studies to compare the clinical and mycological efficacy and safety of fluconazole oral suspension 6 mg/kg/day for 3 and 6 weeks for the treatment of tinea capitis in children 3-12 years of age. With regards to clinical pharmacology and biopharmaceutics, the Sponsor states that no pharmacokinetic trials were planned in the support of this application, and also that no pharmacokinetic trials were requested in the Written Request.

- The Sponsor was originally seeking an indication for Diflucan™ for Oral Suspension in the treatment of tinea capitis in pediatric patents. However, the Sponsor now states that it is not seeking for this indication because the studies presented in this submission did not meet the pre-specified primary efficacy endpoint of demonstrating superiority to the active comparator.

1.2. Reviewer's Comments

1. The proposed drug product, Diflucan™ for Oral Suspension has been approved for treatment of pediatric cryptococcal meningitis and systemic candidal infections in the same strengths as those in the proposed drug product, i.e. 10 mg/mL and 40 mg/mL.
2. The clinical pharmacology of fluconazole has been thoroughly characterized in the treatment of pediatric patients for the above indications with the oral dose of 6 mg/kg/day (NDAs 19-949 and 19-950).
3. For the treatment of acute cryptococcal meningitis, the approved recommended pediatric dosage of fluconazole is 12 mg/kg on the first day, followed by 6 mg/kg once daily. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10-12 weeks after the cerebrospinal fluid becomes culture negative.
4. In the current submission, the firm has conducted three studies to compare the clinical and mycological efficacy and safety of fluconazole oral suspension 6 mg/kg/day for 3 and 6 weeks for the treatment of tinea capitis in children 3-12 years of age.
5. Since, PK characteristics of fluconazole oral suspension 10 mg/mL and 40 mg/mL have already been established with regards to the dosage form and dosing regimen, strengths and pediatric patients, analogous to those in NDA 21-718, the reviewer concurs that conducting new clinical pharmacology and biopharmaceutics studies to support the current application is not needed.

2. Phase IV Commitments

No Phase IV studies are requested.

3. Recommendations

The Office of Clinical Pharmacology and Biopharmaceutics has reviewed the information submitted to the Human Pharmacokinetics and Biopharmaceutics Section of the Pediatric Written Request associated with the NDA 21-718. The information submitted under this section is acceptable.

_____ Date: _____

Chandra S. Chaurasia, Ph.D.
Clinical Pharmacology Reviewer
Division of Pharmaceutical Evaluation III

RD/FT Initialed by E. Dennis Bashaw, Pharm.D. _____Date: _____

CC: NDA 21-718, HFD-850 (P. Lee), HFD-540 (F. Cross), HFD-880 (D. Bashaw, J. Lazor, A. Selen)

End of Document

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Chandra S. Chaurasia
4/6/04 12:01:59 PM
BIOPHARMACEUTICS

Putting this review in DFS again as the one
filed earlier apparently does not have signature page.
Thanks

Dennis Bashaw
4/7/04 12:10:08 PM
BIOPHARMACEUTICS